Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01970696 | International Ovarian & Testicular Stromal Tumor Registry(OTST) | recruiting | — | 300 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 |
| clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06541171 | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results(FOFU) | not yet recruiting | — | 220 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT01511328 | Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm | active not recruiting | N/A | 270,000 | Karolinska InstitutetOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06404671 | Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer | recruiting | N/A | 250 | Alexandria UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06393543 | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis(STICRISC) | not yet recruiting | — | 600 | Radboud University Medical CenterOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03732950 | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06315270 | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | not yet recruiting | — | 100 | The First Hospital of Jilin UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06230549 | Adaptive Radiotherapy in Patients With Gynecological Tumors(ProART) | recruiting | N/A | 30 | University Hospital, EssenOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06202339 | Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT). | not yet recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 0 | Jan 31, 2024 | clinicaltrials |
| NCT06066216 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | not yet recruiting | Phase 2 | 45 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 23, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05613283 | Primary Cervical Cancer Screening by Self-sampling HPV Test(PREVENT) | active not recruiting | — | 17,875 | Peking University People's HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05444270 | Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer(SABR-ROC) | recruiting | N/A | 270 | Yonsei UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | recruiting | Phase 2 | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05406856 | PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer(PROTECT) | recruiting | N/A | 30 | Leiden University Medical CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06039982 | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer | not yet recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05945407 | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | recruiting | N/A | 57 | Peking University People's HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05210270 | HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy(HYACINCT) | not yet recruiting | Phase 1 / Phase 2 | 55 | University of Santo Tomas Hospital, PhilippinesOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT02073500 | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies(PSM) | recruiting | — | 300 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04976478 | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | not yet recruiting | — | 125 | Peking University Third HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04834544 | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care | recruiting | Phase 2 | 75 | Peking University Third HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03025477 | Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer(CHIMOVIP) | recruiting | Phase 2 | 84 | Groupe Hospitalier Diaconesses Croix Saint-SimonOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04515602 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | not yet recruiting | Phase 3 | 410 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Aug 27, 2020 | clinicaltrials |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | recruiting | Phase 3 | 360 | Japanese Gynecologic Oncology GroupOTHER | 2 | Aug 30, 2019 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2024source: clinicaltrials